Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadruple Therapies for H. pylori Eradication in Portugal
NCT05449028Unknown
- Sponsor
- ULS Coimbra
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esomeprazole, amoxicillin, clarithromycin, metronidazole, bismuth subsalicylate and 1 more in Helicobacter pylori infection, sponsored by ULS Coimbra. Primary endpoints: Eradication rate of the different therapeutic regimens at 1 month, Re-infection rate after the different therapeutic regimens at 12 months and 2 more. Status: unknown.
02
Drugs
esomeprazoleamoxicillinclarithromycinmetronidazolebismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05449028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05449028.